Uncategorized
Topical NSAID shows no benefit in stalling progression to center-involved DME
A DRCR.net study determined that after a year of therapy with topical nepafenac, eyes with non-center-involved diabetic macular edema were no less likely to progress to center-involved disease than non-treated eyes.Prevalence data from the Centers for Disease Control suggest that many cases of DME do not involve the central macula, while data from the Early Treatment Diabetic Retinopathy Study and Protein Kinase C Inhibitor Study indicate that 20% to 30% of such cases may have center-involved DME by 1 year.